Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir vs Valganciclovir for CMV Prevention in Kidney Transplant
NCT02439957Phase 3Terminated
- Sponsor
- Chimerix Inc.
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brincidofovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Chimerix Inc. Primary endpoint: The Incidence of Cytomegalovirus (CMV) Disease at 24 weeks. Started Sep 2015; status: terminated.
02
Drugs
brincidofovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02439957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439957.